The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Cytoreductive therapy is safe and feasible for newly-diagnosed AML
Kunhwa Kim, MD, MPH, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, summarizes the results of a post-hoc analysis investigating whether cytoreductive therapy with hydroxyurea or cytarabine can be used as a suitable alternative to immediate induction therapy for urgent disease control in patients with newly-diagnosed acute myeloid leukemia (AML). The study reviewed 276 patients, 35% of whom received cytoreductive therapy prior to starting definitive therapy. No significant difference was found between the complete response (CR) rate, overall survival (OS) or progression-free survival (PFS) of patients who received cytoreduction therapy compared to those who did not. Pretreatment with cytoreductive therapy was found to be safe and feasible in newly-diagnosed AML. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
